Profile data is unavailable for this security.
About the company
Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for patients with cancer and diabetes. The Company’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, who have limited treatment options. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid nanoparticles. The Company’s lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Using a different gene therapy delivery system, the Company is also developing its preclinical diabetes candidate GPX-002 using the same construct for both Type 1 diabetes and Type 2 diabetes. It conducts preclinical research to explore how REQORSA may be administered in other solid tumors.
- Revenue in USD (TTM)0.00
- Net income in USD-27.63m
- Incorporated2009
- Employees26.00
- LocationGenprex Inc1601 Trinity StreetBldg. B, Suite 3.322AUSTIN 78712United StatesUSA
- Phone+1 (512) 537-7997
- Fax+1 (302) 655-5049
- Websitehttps://www.genprex.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NanoString Technologies Inc | 162.47m | -166.43m | 4.43m | 703.00 | -- | -- | -- | 0.0273 | -3.53 | -3.53 | 3.44 | -1.05 | 0.4936 | 2.07 | 4.30 | 231,113.80 | -50.56 | -30.01 | -62.82 | -34.66 | 35.72 | 57.14 | -102.44 | -80.87 | 2.02 | -70.17 | 1.29 | -- | -12.28 | 2.06 | -38.43 | -- | 40.03 | -- |
| Ensysce Biosciences Inc | 1.75m | -11.55m | 4.47m | 7.00 | -- | 1.15 | -- | 2.56 | -3.74 | -3.74 | 0.5109 | 0.5115 | 0.3886 | -- | 9.06 | 249,514.30 | -257.00 | -17.68 | -574.02 | -19.42 | -- | -- | -661.34 | -715.78 | -- | -6.25 | 0.0671 | -- | -11.61 | -- | 57.64 | -- | -- | -- |
| Alterola Biotech Inc | 0.00 | -2.88m | 4.51m | 1.00 | -- | -- | -- | -- | -0.0027 | -0.0027 | 0.00 | -0.001 | 0.00 | -- | -- | 0.00 | -47.24 | -- | -63.88 | -- | -- | -- | -- | -- | 0.0019 | -- | -- | -- | -- | -- | 73.07 | -- | -- | -- |
| Gold River Productions Inc. | -100.00bn | -100.00bn | 4.53m | 1.00k | -- | 6.99 | -- | -- | -- | -- | -- | 0.0005 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -100.11 | -- | -- | -- |
| MyMD Pharmaceuticals Inc | 0.00 | -7.07m | 4.62m | 9.00 | -- | 0.204 | -- | -- | -5.53 | -5.53 | 0.00 | 10.28 | 0.00 | -- | -- | 0.00 | -25.59 | -76.20 | -31.13 | -84.38 | -- | 7.64 | -- | -4,290.96 | -- | -- | 0.00 | -- | -- | -- | 49.15 | -- | -- | -- |
| Genprex Inc | 0.00 | -27.63m | 4.64m | 26.00 | -- | 0.4852 | -- | -- | -19.18 | -19.18 | 0.00 | 4.55 | 0.00 | -- | -- | 0.00 | -153.97 | -92.06 | -202.83 | -98.32 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -29.99 | -- | -7.13 | -- |
| 4Cable TV International Inc | 758.68k | -3.14m | 4.66m | 0.00 | -- | -- | -- | 6.14 | -0.0624 | -0.0624 | 0.0157 | -0.0412 | 1.07 | 1.84 | 25.22 | -- | -441.73 | -82.30 | -- | -308.10 | 29.92 | -- | -414.41 | -47.62 | 0.0064 | -0.5271 | -- | -- | -0.0914 | -- | -731.54 | -- | -- | -- |
| Sonnet Biotherapeutics Holdings Inc | 92.74k | -8.43m | 4.67m | 12.00 | -- | 1.53 | -- | 50.34 | -5.28 | -5.28 | 0.0315 | 0.9813 | 0.0097 | -- | 0.2248 | 7,728.33 | -87.68 | -- | -194.11 | -- | -- | -- | -9,086.22 | -- | -- | -138.21 | 0.00 | -- | -57.76 | -- | 36.64 | -- | -- | -- |
| China Pharma Holdings Inc | 6.42m | -3.56m | 4.68m | 231.00 | -- | 0.5271 | -- | 0.7291 | -0.8352 | -0.8352 | 1.03 | 0.5596 | 0.3828 | 1.93 | 14.14 | 27,795.89 | -21.22 | -29.66 | -44.77 | -55.25 | -11.67 | 6.47 | -55.42 | -73.09 | 0.2523 | -11.34 | 0.261 | -- | -13.48 | -10.68 | 22.50 | -- | -25.78 | -- |
| Pineapple Inc | 157.59k | 376.69k | 4.75m | -- | 0.5834 | -- | 12.47 | 30.15 | 0.1114 | 0.1114 | 0.0028 | -0.0318 | 0.0388 | -- | -- | -- | 9.28 | -- | 53.43 | -- | -412.55 | -- | 239.03 | -- | 0.00 | -- | -- | -- | -- | -- | -611.10 | -- | -- | -- |
| Palisade Bio Inc | 0.00 | -13.49m | 4.84m | 9.00 | -- | 0.4366 | -- | -- | -24.67 | -24.67 | 0.00 | 11.82 | 0.00 | -- | -- | 0.00 | -96.63 | -132.36 | -111.78 | -165.45 | -- | -- | -- | -27,892.32 | -- | -874.31 | 0.00 | -- | -- | -0.7814 | 13.74 | -- | 18.53 | -- |
| Artelo Biosciences Inc | 0.00 | -9.60m | 4.87m | 5.00 | -- | 0.5110 | -- | -- | -3.13 | -3.13 | 0.00 | 2.95 | 0.00 | -- | -- | 0.00 | -66.62 | -- | -70.40 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.87 | -- | -- | -- |
| GB Sciences Inc | 0.00 | -4.03m | 4.91m | 3.00 | -- | -- | -- | -- | -0.0105 | -0.0105 | 0.00 | -0.0119 | 0.00 | -- | -- | 0.00 | -255.86 | -49.16 | -- | -131.40 | -- | 6.03 | -- | -995.19 | -- | -8.63 | -- | -- | -- | -- | -2,715.25 | -- | -60.82 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Armistice Capital LLCas of 31 Mar 2024 | 97.87k | 4.66% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 14.98k | 0.71% |
| Geode Capital Management LLCas of 31 Mar 2024 | 11.99k | 0.57% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 11.39k | 0.54% |
| Tower Research Capital LLCas of 31 Mar 2024 | 2.77k | 0.13% |
| Group One Trading LPas of 31 Mar 2024 | 828.00 | 0.04% |
| Morgan Stanley & Co. LLCas of 31 Mar 2024 | 791.00 | 0.04% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 2024 | 704.00 | 0.03% |
| UBS Financial Services, Inc.as of 31 Mar 2024 | 591.00 | 0.03% |
| Merrill Lynch International (Investment Management)as of 31 Mar 2024 | 411.00 | 0.02% |
